Every earnings call for STAR — management tone, guidance, KPIs and promise tracking, quarter by quarter.
STAR · 5 transcripts · Healthcare · latest Q4 FY26Strides Pharma Science Limited has 5 earnings calls on record here, a Healthcare company, most recently Q4 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
Revenue (FY26) 48587 million (+6% YoY); EBITDA (FY26) ₹925 cr (+15% YoY); EBITDA Margin (FY26) 19%. EBITDA compounded at approximately 26% over the last 3 years, with EBITDA margin expanding 400 bps to 19% in FY26.
Read full transcript & analysisRevenue ₹1,192 cr (+4% YoY); EBITDA ₹236 cr (+12% YoY); EBITDA Margin 19.8%. Gross margins exceeded 60%, with overall gross margins at 59.8%.
Read full transcript & analysisEBITDA (Q2) ₹232 cr (+25% YoY); EBITDA Margin (Q2) 19%; Reported PAT (Q2) ₹132 cr. Revenue grew by 4.6% YoY in Q2 FY26.
Read full transcript & analysisRevenue ₹1,120 cr; EBITDA ₹218 cr (+15% YoY); EBITDA Margin 19.5%. Revenue of ₹1,120 crores in Q1 FY26.
Read full transcript & analysisFY25 EBITDA ₹803 cr (+37% YoY); FY25 EBITDA Margin 17.6%; FY25 Reported EPS ₹44.05. FY25 Revenue grew 17.2%, exceeding guidance of 12-15%.
Read full transcript & analysis